Evommune, Inc. (EVMN): EPS (Diluted)
-$11.22
Year ended 2025-12-31
| Period ended | EPS (Diluted) | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$11.22 | n/m | 2026-03-05, From 2025-01-01 |
| 2024-12-31 | -$45.29 | n/a | 2026-03-05, From 2024-01-01 |
EPS (Diluted) at similar companies
| Company | Year ended | EPS (Diluted) | Change YoY |
|---|---|---|---|
| Evommune, Inc. (EVMN) | 2025-12-31 | -$11.22 | n/m |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | -$14.57 | n/m |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | -$0.12 | n/m |
| CV Sciences, Inc. (CVSI) | 2025-12-31 | -$0.01 | n/m |
| Pyxis Oncology, Inc. (PYXS) | 2025-12-31 | -$1.28 | n/m |
| Prelude Therapeutics Inc (PRLD) | 2025-12-31 | -$1.29 | n/m |
| Arbutus Biopharma Corp (ABUS) | 2025-12-31 | -$0.17 | n/m |
| Opus Genetics, Inc. (IRD) | 2025-12-31 | -$0.80 | n/m |
| Jaguar Health, Inc. (JAGX) | 2025-12-31 | -$22.97 | n/m |
Compare EVMN, TNXP, EMMA, CVSI side by side · Screen every company in Pharmaceutical Preparations ↗